197 results Stibbe advises Egeria Stibbe advises Egeria on the sale of its 40% interest in railroad maintenance company ASSET Rail to Arcadis and Dura Vermeer. Stibbe advises Aedifica Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on its acquisition of four senior housing sites in The Netherlands. Stibbe represents CEO of Royal Brinkers group of companies Stibbe represented the director and sole shareholder of the Royal Brinkers group of companies in a insolvency litigation matter. In 2010, the majority of entities within the Royal Brinkers group went bankrupt as a result of changed market conditions. Stibbe represents Mylan On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion. Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here. Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b Stibbe represents Supervisory Board members of FC Twente Stibbe represented members of the Supervisory Board of the Dutch professional football club FC Twente when the club faced financial difficulties in 2016. Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products. Stibbe advises Zeeland Seaports on the bankruptcy of Thermphos Stibbe advises N.V. Zeeland Seaports ("ZSP") on the bankruptcy of Thermphos International B.V. ("Thermphos"), one of the world's largest producers of phosphorus before it was declared bankrupt in November 2012. Stibbe advises Merin (formerly Uni-Invest) Advising Merin (formerly Uni-Invest) on the restructuring of its of its approximately EUR 790 million outstanding CMBS and Mezzanine loans and the sale of the company to Patron Capital and TPG Capital. Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises the Gemeentelijke Holding Stibbe advised the directors of the Gemeentelijke Holding, one of the main historical shareholders of Dexia NV, throughout the entire crisis period. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Pagination Previous page Page 8 Page 9 Current page 10 Page 11 Next page
Stibbe advises Egeria Stibbe advises Egeria on the sale of its 40% interest in railroad maintenance company ASSET Rail to Arcadis and Dura Vermeer.
Stibbe advises Aedifica Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on its acquisition of four senior housing sites in The Netherlands.
Stibbe represents CEO of Royal Brinkers group of companies Stibbe represented the director and sole shareholder of the Royal Brinkers group of companies in a insolvency litigation matter. In 2010, the majority of entities within the Royal Brinkers group went bankrupt as a result of changed market conditions.
Stibbe represents Mylan On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition
Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.
Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.
Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b
Stibbe represents Supervisory Board members of FC Twente Stibbe represented members of the Supervisory Board of the Dutch professional football club FC Twente when the club faced financial difficulties in 2016.
Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.
Stibbe advises Zeeland Seaports on the bankruptcy of Thermphos Stibbe advises N.V. Zeeland Seaports ("ZSP") on the bankruptcy of Thermphos International B.V. ("Thermphos"), one of the world's largest producers of phosphorus before it was declared bankrupt in November 2012.
Stibbe advises Merin (formerly Uni-Invest) Advising Merin (formerly Uni-Invest) on the restructuring of its of its approximately EUR 790 million outstanding CMBS and Mezzanine loans and the sale of the company to Patron Capital and TPG Capital.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises the Gemeentelijke Holding Stibbe advised the directors of the Gemeentelijke Holding, one of the main historical shareholders of Dexia NV, throughout the entire crisis period.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.